Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (692)	1/16/2004 2:43:41 PM
From: Icebrg	Read Replies (1) \| Respond to of 717

>>Journal of Clinical Oncology>> The big Question is "Why only for lung cancer" (Or NSCLC to be exact). The article in the journal suggests the following rationale for seeing better results with lung cancer than with other types of cancer. There are several possible reasons why a benefit was observed favoring the MGd and WBRT treatment arm in lung cancer patients for time to both neurocognitive and neurologic progression. Patients with lung cancer in this trial differed substantially from patients with breast and other cancers; lung cancer patients more often presented with brain metastases at their initial primary tumor diagnosis, diagnosis, had brain as the only known site of metastases, had smaller lesion volume, and had less prior therapy [28]. It is likely that less extensive intracranial disease, more rapid and reversible development of CNS signs and symptoms, and less exposure to potentially neurotoxic chemotherapies provide a greater opportunity to demonstrate a benefit in this subgroup. Recently, Sperduto et al [34], in a study of WBRT with or without stereotactic radiosurgery in patients with one to three brain metastases, similarly observed a treatment benefit in a lung cancer subgroup. Although from the suggested explanation the reason doesn't seem to have so much to do with type of cancer as with the status and progression of the disease. Erik